Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen 
Welcome,         Profile    Billing    Logout  
 11 Diseases   24 Trials   24 Trials   1081 News 


12345678910111213...1314»
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Enrollment open:  EVOLVE Study: The Real-life Clinical Practice With Tezepelumab in Greece (clinicaltrials.gov) -  Jan 28, 2025   
    P=N/A,  N=150, Recruiting, 
    Other biological therapies, including tezepelumab, have no important effect on patient-relevant outcomes. Not yet recruiting --> Recruiting
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  SUNRISE: Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma (clinicaltrials.gov) -  Jan 9, 2025   
    P3,  N=124, Active, not recruiting, 
    Benralizumab, dupilumab, and tezepelumab have been reported to improve both ECRS and complicated bronchial asthma. Recruiting --> Active, not recruiting | N=207 --> 124 | Trial completion date: Dec 2025 --> Mar 2025 | Trial primary completion date: Sep 2025 --> Mar 2025
  • ||||||||||  Review, Journal:  Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways. (Pubmed Central) -  Dec 20, 2024   
    While multiple therapeutic antibodies have been approved for clinical use, scientists are still working on ways to improve on current treatment approaches. Here, we provide context to understand therapeutic targeting strategies and their limitations, discussing both knowledge gaps and promising future directions to enhancing clinical efficacy in allergic disease management.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Retrospective data, Review, Journal:  Long-term safety of tezepelumab in patients with asthma: a systematic review and meta-analysis of randomized controlled trials. (Pubmed Central) -  Dec 17, 2024   
    There was no statistically significant difference in the proportion of patients with at least one adverse event (AE), AEs leading to discontinuation of study treatment, all-cause death, influenza, bronchitis, nasopharyngitis, headache, and hypertension between the two groups. Long-term (12-52 weeks) use of tezepelumab in patients with asthma does not increase the incidence of adverse events.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Review, Journal, Stroma:  Thymic Stromal Lymphopoietin (TSLP): Evidence in Respiratory Epithelial-driven Diseases Including Chronic Rhinosinusitis with Nasal Polyps. (Pubmed Central) -  Dec 5, 2024   
    The role of TSLP in asthma is well established and supported by the efficacy of tezepelumab, the first anti-TSLP monoclonal antibody approved for both type 2 (T2)-high and T2-low severe asthma...While further research is required to clarify the extent of TSLP contribution in CRSwNP, this review highlights the potential of anti-TSLP therapies as a novel approach for managing severe, uncontrolled CRSwNP. If these preliminary findings are confirmed, targeting TSLP could become a promising strategy to treat CRSwNP with or without comorbid asthma.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Journal:  Exploratory Analysis of the Economically Justifiable Price of Tezepelumab for asthma severe in Colombia. (Pubmed Central) -  Dec 4, 2024   
    The economically justifiable cost for tezepelumab in Colombia is between U$795 to U$3384 per dose, depending on the WTP used to decide its implementation. This result should encourage more studies in the region that optimize decision-making processes when incorporating this drug into the health plans of each country.
  • ||||||||||  Review, Journal:  Therapies for Chronic Spontaneous Urticaria: Present and Future Developments. (Pubmed Central) -  Nov 27, 2024   
    Additionally, molecules targeting the Mas-related G protein-coupled receptor X2 (MRGPRX2), and those inhibiting the tyrosine kinase receptor Kit, such as barzolvolimab, show promise in clinical studies...Further research is essential to better elucidate the pathophysiology of CSU and optimize treatment protocols to achieve long-term benefits in managing this condition. Altogether, the future of CSU treatments that target pathogenetic mechanisms seems promising.
  • ||||||||||  Journal:  The new biologic drugs: Which children with asthma should get what? (Pubmed Central) -  Nov 27, 2024   
    We must be especially aware of the dangers of extrapolating data from adults to children, because the pathophysiology and role of biomarkers may differ significantly from adult asthma. Given the current level of knowledge, even after treatment has been initiated, children should be regularly reviewed to determine the efficacy of treatment, side-effect profile and consideration of when treatment with the biologic should be discontinued.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Journal:  Efficacy of tezepelumab in patients with severe asthma and persistent airflow obstruction. (Pubmed Central) -  Nov 26, 2024   
    For patients with PAO at baseline, the proportion without PAO at week 52 was higher with tezepelumab (12.1%) than placebo (6.6%) (odds ratio 1.96, 95% CI: 1.30-2.94). Tezepelumab improved lung function and reduced exacerbations versus placebo in patients with severe, uncontrolled asthma with and without PAO.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Journal:  Tezepelumab in Patients With Severe Asthma: Response at 3 Months. (Pubmed Central) -  Nov 25, 2024   
    Tezepelumab improved lung function and reduced exacerbations versus placebo in patients with severe, uncontrolled asthma with and without PAO. No abstract available
  • ||||||||||  Journal:  Drugs for asthma. (Pubmed Central) -  Nov 19, 2024   
    Though having more choices was associated with better patient selection for omalizumab, this was inconsistent for other biologics. No abstract available
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Review, Journal:  Positioning tezepelumab for patients with severe asthma: from evidence to unmet needs. (Pubmed Central) -  Nov 18, 2024   
    Based on positive clinical trial results, TZP appears to offer a promising, safe, and effective treatment approach. This narrative review examines the evidence for treating severe asthma with TZP, analyses clinical trial findings, and provides clinicians with practical insights into identifying patients who may respond best to this novel biologic therapy.
  • ||||||||||  Journal:  'Efficacy of biologics in NSAID-ERD: United airways from the nose to the bronchi'. (Pubmed Central) -  Nov 13, 2024   
    Herein we will review the currently available clinical trial and real-world evidence for biologic efficacy and safety patients with NSAID-ERD, discuss the mechanisms of biologic therapy specific to NSAID-ERD, and review evidence regarding the use of biologic therapy versus endoscopic sinus surgery therapy for CRSwNP and NSAID-ERD. We will propose a management approach for choosing biologic therapy or endoscopic sinus surgery with aspirin therapy after desensitization for patients with NSAID-ERD.
  • ||||||||||  Journal:  Current goals of NSAID-ERD management: patient-centered approaches involving NSAID desensitization with and without biologics. (Pubmed Central) -  Nov 13, 2024   
    So far, dupilumab demonstrated greater efficacy in patients with NSAID-ERD than in aspirin-tolerant patients with regard to several clinical outcomes...Additionally, there are conflicting studies as to whether patients on a T2 biologic become desensitized to NSAIDs, as omalizumab proved to restore tolerance to aspirin in only two thirds of patients. This goal of NSAIDs tolerance should be considered as part of disease control future approaches, representing one of many aspects in a patient-centered care approach.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Cost-Effectiveness of Tezepelumab in Taiwan for Severe Asthma () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_3190;    
    Patients who experience an exacerbations result in either a burst in OCS, an A&E visit or hospitalization, the latter resulting in the largest cost and quality of life burden. The results from the analysis show that tezepelumab is dominant and is a cost-effective treatment when compared to the other biologics.
  • ||||||||||  Biosimilars: The Key to Lowering Access Barriers to Omalizumab Across Europe () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_660;    
    The disparities highlighted in this study underscore the need for improvement in access to omalizumab across Europe. This study highlights the need for comprehensive policy reforms and the introduction of omalizumab biosimilar to ensure equitable access to omalizumab across Europe, enhancing patient care and potentially solving shortage issues and expanding treatment options for off-label indications su ch as urticarial vasculitis and food allergy.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Budget Impact of Tezepelumab for the Treatment of Severe Asthma in the Brazilian Private Healthcare System () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_95;    
    In Brazil, available medications include omalizumab for severe allergic asthma (SAA), mepolizumab and benralizumab for severe eosinophilic asthma (SEA), and dupilumab for T2-high asthma. The inclusion of tezepelumab led to significantly lower medical expenses, highlighting its dual clinical and cost-saving impact.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Enrollment closed:  TezepelumabPRO: Tezepelumab PRO Study (clinicaltrials.gov) -  Oct 1, 2024   
    P=N/A,  N=92, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    SEVERE EGPA ? A ROLE FOR TEZEPELUMAB? (Monitor 12; Hall A) -  Sep 29, 2024 - Abstract #ACAAI2024ACAAI_1156;    
    Further study is needed to elucidate whether there may be a broader role for allergic pathway blockade in the treatment paradigms for EGPA. Figure 1 Diagnostics including labs, imaging, and procedures
  • ||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron, Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen, Xolair (omalizumab) / Roche, Novartis
    REFRACTORY ASTHMA UNVEILING HISTOPLASMOSIS: A DIAGNOSTIC CHALLENGE (Monitor 7; Hall A) -  Sep 29, 2024 - Abstract #ACAAI2024ACAAI_973;    
    She has tolerated tezepelumab with open triple therapy however was hospitalized for respiratory distress in October 2023...After three months of itraconazole in addition to her asthma therapies, her histoplasmosis levels returned negative and itraconazole was discontinued...This report aims to explore the diagnostic and management considerations in cases where severe asthma and histoplasmosis co-occur, providing insights into their therapy. Clinical Immunology, Immunodeficiency
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    ENHANCED LUNG FUNCTION IN A PATIENT WITH CYSTIC FIBROSIS AND ABPA TREATED WITH TEZEPELUMAB (Monitor 7; Hall A) -  Sep 29, 2024 - Abstract #ACAAI2024ACAAI_927;    
    Via its mechanism targeting thymic stromal lymphoprotein (TSLP), an upstream alarmin important for epithelial barrier integrity and mucus production, tezepelumab presents an attractive option for cystic fibrosis patients with concomitant allergic pulmonary disease. More research is needed to determine if tezepelumab is safe and effective in these patients.
  • ||||||||||  DUAL BIOLOGIC USE IN SEVERE EOSINOPHILIC ASTHMA (Monitor 7; Hall A) -  Sep 29, 2024 - Abstract #ACAAI2024ACAAI_665;    
    His AEC remained low at 100/ uL, FeNO normalized to 10ppb, and lung function improved. : The complementary use of asthma biologics with different targets in the T2 inflammatory cascade may be a viable solution for patients intolerant or non-responsive to a single drug.